A Phase 1b, Randomised, Controlled Age De-escalation, Dose-finding Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Full-length MSP1/GLA-SE (SUM-101) Malaria Vaccine in Healthy Young Children, and Infants in Burkina Faso
Latest Information Update: 28 Aug 2025
At a glance
- Drugs SUM-101 (Primary) ; Rabies vaccine
- Indications Falciparum malaria; Malaria
- Focus Adverse reactions
- Acronyms SUM-101
Most Recent Events
- 11 Aug 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Jan 2026.
- 11 Aug 2025 Status changed from not yet recruiting to recruiting.
- 08 Jul 2025 Planned End Date changed from 31 Oct 2025 to 31 Aug 2026.